NCT05056220View on ClinicalTrials.gov

Personalized Long-term Human Albumin Treatment in Patients With Decompensated Cirrhosis and Ascites

PHASE3RecruitingINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

February 26, 2024

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions
Decompensated Cirrhosis and Ascites
Interventions
DRUG

Human albumin

20% Human Albumin infusions (every 10th day +/- 4 days) with dosing according to the participants bodyweight (1.5 grams of albumin per kg bodyweight with a maximum of 100 grams)

DRUG

sodium chloride

0.9% NaCl infusions (every 10th day +/- 4 days) with dosing according to the corresponding volume used of 20% Human Albumin (1.5 grams of albumin per kg bodyweight with a maximum of 100 grams)

Trial Locations (12)

5000

RECRUITING

Odense University Hospital, Odense

Unknown

RECRUITING

Katholieke Universiteit Leuven, Leuven

RECRUITING

Herlev Hospital, Herlev

ACTIVE_NOT_RECRUITING

Charité - Universitätsmedizin Berlin, Berlin

NOT_YET_RECRUITING

Universitätsklinikum Jena, Jena

RECRUITING

Universitätsklinikum Münster, Münster

RECRUITING

Debreceni Egyetem, Debrecen

RECRUITING

Academisch Ziekenhuis Leiden, Leiden

RECRUITING

Alrijne Ziekenhuis Leiden, Leiderdorp

RECRUITING

Hospital Clinic Barcelona, Barcelona

RECRUITING

Hospital Del Mar, Barcelona

NOT_YET_RECRUITING

King's College Hospital, London

All Listed Sponsors
collaborator

EASL - CLIF Consortium

OTHER

lead

Aleksander Krag

OTHER